Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham Requip for Parkinson's study shows 24% improvement in motor functioning.

Executive Summary

SMITHKLINE REQUIP FOR PARKINSON's IMPROVES MOTOR FUNCTION 24% compared to a 3% decline on placebo, according to results from one of three Phase III studies of ropinirole presented at the American Academy of Neurology meeting in San Francisco March 26. The 24% improvement was statistically significant compared to placebo-treated patients with Parkinson's disease who had no or little exposure to dopaminergic anti-Parkinson therapy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel